Use of steroid in aloppecia

Reading File
Finding Sources
Finding Sources
Searching PubMed

"alopecia areata"[MeSH Terms] AND "corticosteroids"[MeSH Terms]

Reading File
Reading File
Reading File
Reading File
Reading File
Searching Images

alopecia areata intralesional steroid injection scalp

This clinical photograph shows a close-up, superior-lateral view of the scalp of a patient with severe alopecia areata. The image reveals multiple large, well-demarcated, non-scarring patches of alopecia (hair loss). The exposed scalp skin appears smooth, pale, and lacks follicular ostia plugging, which is characteristic of non-cicatricial alopecia. Within the bald patches, a few vellus hairs and some short, broken hairs are visible. Minor erythematous punctate lesions are present on the bare scalp surface, possibly related to recent intralesional treatments. The remaining hair is dark, terminal, and demonstrates normal density and length in unaffected regions. This visual presentation is typical of autoimmune hair loss, where the disease progresses from focal patches toward more extensive involvement such as alopecia totalis. The photograph serves as a clinical reference for diagnosing patchy hair loss and monitoring disease activity and treatment response in dermatological settings.

This clinical photograph shows a close-up, superior-lateral view of the scalp of a patient with severe alopecia areata. The image reveals multiple large, well-demarcated, non-scarring patches of alopecia (hair loss). The exposed scalp skin appears smooth, pale, and lacks follicular ostia plugging, which is characteristic of non-cicatricial alopecia. Within the bald patches, a few vellus hairs and some short, broken hairs are visible. Minor erythematous punctate lesions are present on the bare scalp surface, possibly related to recent intralesional treatments. The remaining hair is dark, terminal, and demonstrates normal density and length in unaffected regions. This visual presentation is typical of autoimmune hair loss, where the disease progresses from focal patches toward more extensive involvement such as alopecia totalis. The photograph serves as a clinical reference for diagnosing patchy hair loss and monitoring disease activity and treatment response in dermatological settings.

This composite educational graphic presents clinical and trichoscopic comparisons of alopecia areata treatment outcomes over a three-month period. The image is divided into two main comparison groups: a treated representative patch and an untreated control patch. 

Panels (a) and (b) show the clinical progression of a well-defined, smooth, non-scarring bald patch on the scalp. Panel (a) illustrates the baseline lesion, while panel (b) demonstrates significant hair regrowth and closure of the patch following topical steroid treatment. Corresponding trichoscopic images (c) and (d) provide high-magnification views; panel (c) shows the baseline with sparse terminal hairs and visible follicular openings, while (d) reveals a marked increase in terminal hair density and thickness. 

Panels (e) through (h) represent the control patch. Clinical images (e) and (f) show a persistent alopecic area with no significant clinical change. Trichoscopic views (g) and (h) confirm minimal hair regrowth, maintaining low hair density. This visual material serves to illustrate diagnostic trichoscopic features of alopecia areata and the quantifiable visual markers used to assess therapeutic efficacy in dermatology.

This composite educational graphic presents clinical and trichoscopic comparisons of alopecia areata treatment outcomes over a three-month period. The image is divided into two main comparison groups: a treated representative patch and an untreated control patch. Panels (a) and (b) show the clinical progression of a well-defined, smooth, non-scarring bald patch on the scalp. Panel (a) illustrates the baseline lesion, while panel (b) demonstrates significant hair regrowth and closure of the patch following topical steroid treatment. Corresponding trichoscopic images (c) and (d) provide high-magnification views; panel (c) shows the baseline with sparse terminal hairs and visible follicular openings, while (d) reveals a marked increase in terminal hair density and thickness. Panels (e) through (h) represent the control patch. Clinical images (e) and (f) show a persistent alopecic area with no significant clinical change. Trichoscopic views (g) and (h) confirm minimal hair regrowth, maintaining low hair density. This visual material serves to illustrate diagnostic trichoscopic features of alopecia areata and the quantifiable visual markers used to assess therapeutic efficacy in dermatology.

This image depicts a dermatologic clinical photograph of alopecia areata involving the lateral scalp. Imaging modality: clinical photography with macro close-up view of scalp skin and hair follicles, captured without illumination modifiers or contrast. The primary subject is a localized alopecic patch on the lateral scalp, best described as a round to oval, well-demarcated area of hair loss. The overlying skin appears normal in texture, with preserved epidermis and minor surface desquamation or perifollicular subtle erythema not readily observable in non-dermoscopic photography. Hair density within the patch is markedly reduced with visible expansion of follicular openings at the border and intact surrounding hair. The lesion is non-scarring, with no obvious scarring plaques or scarring tracts; there is no evidence of ornamentation or scaly scale. This presentation is characteristic of alopecia areata, a non-scarring autoimmune condition associated with peribulbar lymphocytic infiltrates histologically. Clinically significant for differential diagnosis against tinea capitis, traction alopecia, androgenetic alopecia, and lichen planopilaris. This image is valuable for education, tele-dermatology, and case repositories, enabling recognition of patchy alopecia patterns, conferral of prognosis, and assessment of treatment response to topical or intralesional corticosteroids and immunomodulatory therapies. Useful in training, patient counseling, and multi-disciplinary discussion.

This image depicts a dermatologic clinical photograph of alopecia areata involving the lateral scalp. Imaging modality: clinical photography with macro close-up view of scalp skin and hair follicles, captured without illumination modifiers or contrast. The primary subject is a localized alopecic patch on the lateral scalp, best described as a round to oval, well-demarcated area of hair loss. The overlying skin appears normal in texture, with preserved epidermis and minor surface desquamation or perifollicular subtle erythema not readily observable in non-dermoscopic photography. Hair density within the patch is markedly reduced with visible expansion of follicular openings at the border and intact surrounding hair. The lesion is non-scarring, with no obvious scarring plaques or scarring tracts; there is no evidence of ornamentation or scaly scale. This presentation is characteristic of alopecia areata, a non-scarring autoimmune condition associated with peribulbar lymphocytic infiltrates histologically. Clinically significant for differential diagnosis against tinea capitis, traction alopecia, androgenetic alopecia, and lichen planopilaris. This image is valuable for education, tele-dermatology, and case repositories, enabling recognition of patchy alopecia patterns, conferral of prognosis, and assessment of treatment response to topical or intralesional corticosteroids and immunomodulatory therapies. Useful in training, patient counseling, and multi-disciplinary discussion.

Reading File
Reading File
I now have rich, detailed content from multiple authoritative dermatology textbooks. Let me compile the comprehensive answer.

Use of Steroids in Alopecia

Steroids are the most widely used treatment for alopecia areata (AA), the main form of inflammatory alopecia where steroids are indicated. They can be delivered by three routes: topical, intralesional, and systemic (oral/pulse). The choice depends on extent, severity, age, and disease progression.

1. Pathophysiologic Basis for Steroid Use

Alopecia areata is an autoimmune, T-cell mediated disease. Autoreactive CD8+NKG2D+ cytotoxic T cells (driven by a Th1/IFN-gamma response) infiltrate the hair follicle bulb ("swarm of bees" peribulbar infiltrate), collapse the immune privilege of the anagen follicle, and cause the follicle to transition from anagen to catagen - resulting in hair loss. The JAK-STAT pathway is central to sustaining this attack. Corticosteroids suppress this inflammatory process broadly by inhibiting T-cell activation, cytokine production (IL-2, IFN-gamma, TNF-alpha), and reducing the peribulbar infiltrate.
  • Andrews' Diseases of the Skin, p. 869
  • Dermatology 2-Volume Set 5e, p. 3328-3330

2. Topical Corticosteroids

Indication: Mild-to-moderate patchy AA; can be used in children and adults. First-line for initial treatment.
Drug/Potency:
  • Ultrapotent (Class I) topical corticosteroids are preferred - e.g., clobetasol propionate 0.05% cream/lotion
  • Can be applied under occlusion for acute or more severe patches
  • Less reliable than intralesional injections but safer and non-invasive
Response: A comparative trichoscopic study (see image below) demonstrates significant regrowth of terminal hair after 3 months of topical steroid treatment vs. untreated control patches.
Alopecia areata before and after topical steroid treatment - trichoscopic comparison
Limitations: Less effective than intralesional injection; risk of skin atrophy with prolonged use, especially on the face.
  • Dermatology 5e, p. 3383

3. Intralesional Corticosteroids (ILC)

Indication: Treatment of choice for localized, cosmetically conspicuous patches - especially frontal hairline, eyebrows, beard, and isolated scalp patches.
Drug: Triamcinolone acetonide (TA)
ParameterDetail
Concentration2.5-5 mg/mL (up to 10 mg/mL)
TechniqueInjected into mid-to-deep dermis, or superficial subcutaneous tissue
Volume per site~0.1 mL per injection site
SpacingInjection sites 1 cm apart
Max dose per session10-20 mg in an average adult
FrequencyEvery 3-4 weeks
Risks:
  • Skin atrophy - more likely with large volumes and higher concentrations
  • Retinal artery embolization (rare but serious) - risk increased with injection under high pressure or via small-bore syringe
  • Subcutaneous fat atrophy (lipodystrophy)
Severe alopecia areata - patchy hair loss on scalp, with minor erythematous punctate lesions consistent with recent intralesional treatment
  • Andrews' Diseases of the Skin, p. 869
  • Dermatology 5e, p. 3385

4. Systemic Corticosteroids

Indication: Rapidly progressive or widespread disease, alopecia totalis, extensive patchy AA. Not useful in ophiasis (band-like peripheral scalp loss) or long-standing alopecia totalis/universalis.

4a. Oral Daily Steroids

  • Prednisolone: Initial dose 0.4-0.6 mg/kg/day
  • Gradual taper over at least 12 weeks
  • Possible transition to a pulse regimen after stabilization
  • Used for rapidly progressive disease

4b. Pulse Systemic Steroids

This is the preferred systemic corticosteroid strategy to reduce cumulative steroid exposure:
RegimenDoseNotes
Methylprednisolone pulse500 mg/day IV for 3 days, repeated monthlyIn adults; 5 mg/kg twice daily over 3 days in children
Dexamethasone pulse0.1 mg/kg orally twice weeklyOral pulse option
Prednisolone weekly pulse200 mg orally once weeklyOral pulse option
Prednisolone monthly pulse5 mg/kg (up to 300 mg) once monthlyUsed in children and adults
Response rates with pulse methylprednisolone (study of 66 patients aged 9-60 years):
  • 60% of patients with widespread patchy AA responded
  • ~50% with alopecia totalis had a good response
  • ~25% with alopecia universalis responded
  • Ophiasic AA did not respond
Predictors of good response:
  • Disease duration 6 months or less
  • Age of onset younger than 10 years
  • Multifocal disease pattern
  • Goldman-Cecil Medicine, p. 1417
  • Andrews' Diseases of the Skin, p. 869
  • Dermatology 5e, p. 3390-3391

5. Steroid-Sparing Agents (used alongside or after steroids)

When long-term steroid therapy is needed, steroid-sparing agents are combined to reduce cumulative steroid toxicity:
  • Cyclosporine: 3-5 mg/kg/day (first choice steroid-sparing agent)
  • Methotrexate: 15-20 mg weekly (adults); ~0.4 mg/kg/week in children
  • Mycophenolate mofetil, azathioprine, dapsone, sulfasalazine - limited data
  • Dermatology 5e, p. 3391

6. Summary: Steroid Selection by Disease Extent

Disease ExtentPreferred Steroid Approach
Single/few patchesIntralesional triamcinolone acetonide 2.5-5 mg/mL every 3-4 weeks
Moderate patchy AAUltrapotent topical corticosteroid +/- intralesional TA
Rapidly progressive/widespreadPulse prednisolone or methylprednisolone; consider daily prednisolone 0.4-0.6 mg/kg/day
Alopecia totalis (acute)Pulse corticosteroids - partial response in ~50%
Alopecia universalisPulse corticosteroids - limited response (~25%); prefer JAK inhibitors
OphiasisSteroids are NOT effective; use contact immunotherapy or JAK inhibitors
Eyebrow AAIntralesional TA is preferred

7. Important Cautions

  • Long-term systemic steroid use carries risks of HPA axis suppression, osteoporosis, weight gain, hypertension, and infection - risks must be carefully weighed against benefits
  • Hair regrowth achieved with steroids may not be sustained after discontinuation; AA is a relapsing disease
  • JAK inhibitors (baricitinib, ritlecitinib) are now FDA-approved for severe AA in adults and adolescents aged 12+ and are increasingly preferred over prolonged systemic steroids for extensive disease
  • Spontaneous remission occurs in 34-50% of patients within 1 year, making anecdotal reports of treatment success difficult to interpret

Sources:
  • Andrews' Diseases of the Skin - Clinical Dermatology, Chapter 33
  • Dermatology 2-Volume Set 5e, Chapter 69
  • Goldman-Cecil Medicine, Chapter 409
  • Fitzpatrick's Dermatology, Volumes 1 & 2

Effect on zinc on hair loss

Finding Sources
Finding Sources
Searching PubMed

"zinc" AND "hair loss" AND "alopecia"

Reading File
Reading File
Reading Article

PMID: 39440586

Reading File
Finding Sources
Searching Images

zinc deficiency alopecia acrodermatitis enteropathica skin hair loss

A composite of four clinical photographs demonstrating the systemic dermatological and mucosal manifestations of Acrodermatitis Enteropathica (AE) in a pediatric patient. The top-left panel shows the scalp with diffuse alopecia and dyspigmented, lightened hair. The top-right panel displays the orofacial region, highlighting beefy red glossitis of the tongue and perioral dermatitis. The bottom-left panel illustrates the lower extremities, featuring widespread hyperpigmented patches, skin erosions, and a prominent flaccid bulla on the shin, with one limb partially bandaged. The bottom-right panel depicts the abdomen, characterized by extensive hyperpigmentation and scattered erosive lesions. Collectively, these images illustrate the classic clinical triad of zinc deficiency: periorificial dermatitis, alopecia, and diarrhea-associated systemic skin breakdown. The presentation is essential for medical students and clinicians for the diagnostic recognition of nutritional deficiencies and zinc malabsorption syndromes.

A composite of four clinical photographs demonstrating the systemic dermatological and mucosal manifestations of Acrodermatitis Enteropathica (AE) in a pediatric patient. The top-left panel shows the scalp with diffuse alopecia and dyspigmented, lightened hair. The top-right panel displays the orofacial region, highlighting beefy red glossitis of the tongue and perioral dermatitis. The bottom-left panel illustrates the lower extremities, featuring widespread hyperpigmented patches, skin erosions, and a prominent flaccid bulla on the shin, with one limb partially bandaged. The bottom-right panel depicts the abdomen, characterized by extensive hyperpigmentation and scattered erosive lesions. Collectively, these images illustrate the classic clinical triad of zinc deficiency: periorificial dermatitis, alopecia, and diarrhea-associated systemic skin breakdown. The presentation is essential for medical students and clinicians for the diagnostic recognition of nutritional deficiencies and zinc malabsorption syndromes.

A composite of three clinical photographs (A, B, C) showing a pediatric patient following two months of treatment for acrodermatitis enteropathica. Panel A illustrates the diaper area (buttocks and perianal region), showing significant resolution of previous erythematous, scaly, and pustular lesions; the skin appears mostly clear with minimal residual faint pink patches within the gluteal folds. Panel B displays the infant's face, demonstrating remission of perioral and periorificial dermatitis, with a clear facial complexion and absence of acute inflammation around the mouth and nose. Panel C provides a posterior view of the scalp, showing successful hair regrowth following previous diffuse alopecia. The hair is light-colored, fine, and demonstrates uniform density without visible thinning or patchy hair loss. Collectively, these images document clinical improvement and therapeutic response to zinc supplementation, highlighting the remission of characteristic periorificial skin manifestations and hair loss associated with metabolic zinc deficiency.

A composite of three clinical photographs (A, B, C) showing a pediatric patient following two months of treatment for acrodermatitis enteropathica. Panel A illustrates the diaper area (buttocks and perianal region), showing significant resolution of previous erythematous, scaly, and pustular lesions; the skin appears mostly clear with minimal residual faint pink patches within the gluteal folds. Panel B displays the infant's face, demonstrating remission of perioral and periorificial dermatitis, with a clear facial complexion and absence of acute inflammation around the mouth and nose. Panel C provides a posterior view of the scalp, showing successful hair regrowth following previous diffuse alopecia. The hair is light-colored, fine, and demonstrates uniform density without visible thinning or patchy hair loss. Collectively, these images document clinical improvement and therapeutic response to zinc supplementation, highlighting the remission of characteristic periorificial skin manifestations and hair loss associated with metabolic zinc deficiency.

A series of nine clinical photographs (a-i) illustrating the cutaneous manifestations and therapeutic response of acrodermatitis enteropathica-like lesions in an infant. Images a-f depict the pre-treatment state, characterized by well-demarcated, erythematous, and erosive plaques with overlying scaly crusts and scabs. The distribution is classic for zinc deficiency, primarily affecting the acral and periorificial regions: occipital scalp (a, b), perioral area (c), auricle (d), and the perineal and perianal zones (e, f). Diffuse alopecia and sparse hair growth are also visible on the scalp. Images g-i demonstrate the clinical status after 6 days of oral zinc supplementation, showing rapid and significant improvement. The inflammatory erythema and erosions on the scalp (g) and anogenital region (h, i) have largely resolved, leaving behind smooth skin with minimal residual post-inflammatory changes. This comparison serves as a pedagogical tool for recognizing the diagnostic distribution of zinc deficiency-related dermatitis and its dramatic response to targeted replacement therapy.

A series of nine clinical photographs (a-i) illustrating the cutaneous manifestations and therapeutic response of acrodermatitis enteropathica-like lesions in an infant. Images a-f depict the pre-treatment state, characterized by well-demarcated, erythematous, and erosive plaques with overlying scaly crusts and scabs. The distribution is classic for zinc deficiency, primarily affecting the acral and periorificial regions: occipital scalp (a, b), perioral area (c), auricle (d), and the perineal and perianal zones (e, f). Diffuse alopecia and sparse hair growth are also visible on the scalp. Images g-i demonstrate the clinical status after 6 days of oral zinc supplementation, showing rapid and significant improvement. The inflammatory erythema and erosions on the scalp (g) and anogenital region (h, i) have largely resolved, leaving behind smooth skin with minimal residual post-inflammatory changes. This comparison serves as a pedagogical tool for recognizing the diagnostic distribution of zinc deficiency-related dermatitis and its dramatic response to targeted replacement therapy.

Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive material from multiple authoritative sources. Let me compile the full answer.

Effect of Zinc on Hair Loss

1. Role of Zinc in Hair Follicle Biology

Zinc is an essential trace mineral that plays multiple roles in maintaining normal hair growth:
  • Enzymatic function: Zinc is a cofactor for over 300 enzymes, including RNA polymerases and alkaline phosphatase - both essential for the rapid cell division required in the hair matrix. Low alkaline phosphatase levels are in fact a useful marker of zinc deficiency.
  • Protein synthesis: Hair is primarily keratin; zinc supports keratinocyte proliferation and protein synthesis in the follicular bulb.
  • 5-alpha-reductase inhibition: Zinc inhibits the enzyme 5-alpha-reductase (which converts testosterone to DHT), offering a potential role in limiting androgenetic alopecia.
  • Immune modulation: Zinc is required for normal T-cell function and immune homeostasis; deficiency impairs immune defense, which can dysregulate follicular cycling.
  • Antioxidant protection: Zinc has antioxidant properties that may protect the skin and follicles from UV-induced and oxidative damage.
  • Yamada's Textbook of Gastroenterology, 7e
  • Dermatology 2-Volume Set 5e, p. 218

2. Zinc Deficiency and Hair Loss

A. Clinical Presentation

Zinc deficiency - whether inherited or acquired - is a well-established cause of generalized alopecia. Hair loss occurs as part of a broader clinical triad:
Triad of zinc deficiency: Dermatitis + Diarrhea + Alopecia (complete triad seen in only ~20% of patients)
Additional skin/appendage features alongside alopecia:
  • Periorificial and acral erosive/pustular/crusting dermatitis
  • Paronychia and onychodystrophy (nail changes)
  • Angular cheilitis and stomatitis
  • Blepharitis and conjunctivitis
  • Superimposed Candida and staphylococcal skin infections
  • Dermatology 5e, p. 220-222
  • Andrews' Diseases of the Skin, p. 2916

B. Inherited Zinc Deficiency: Acrodermatitis Enteropathica (AE)

FeatureDetail
InheritanceAutosomal recessive
GeneSLC39A4 (encodes zinc transporter ZIP4)
PresentationOnset within 1-2 weeks after weaning from breast milk
Hair findingsDiffuse alopecia of scalp, eyebrows, and eyelashes
AssociatedPeriorificial dermatitis, diarrhea, growth retardation, irritability
TreatmentLifelong zinc supplementation: 3 mg/kg/day
Acrodermatitis enteropathica - diffuse alopecia with periorificial dermatitis, bullous skin lesions and glossitis in a pediatric patient

C. Acquired Zinc Deficiency

Causes include:
  • Alcoholism (poor intake + increased urinary excretion)
  • Malabsorption syndromes (IBD, celiac disease, short bowel)
  • Parenteral nutrition without adequate zinc
  • Anorexia nervosa
  • Pregnancy (increased zinc requirement)
  • Vegan/phytate-rich diets (phytate binds zinc, reducing bioavailability - endemic in Middle East/North Africa)
  • Chronic renal failure, HIV disease, sickle cell disease
  • Drugs: penicillamine, diuretics, antacids, quinolones (reduce zinc absorption)
Hair loss in acquired deficiency is reversible with zinc repletion.
  • Andrews' Diseases of the Skin, p. 2906-2913
  • Dermatology 5e, p. 224-230

D. Hair Regrowth After Zinc Supplementation

Zinc replacement results in dramatic and rapid reversal of alopecia in deficient patients. The image below demonstrates complete hair regrowth after zinc supplementation in a child with acrodermatitis enteropathica:
Complete hair regrowth after 2 months of zinc supplementation in acrodermatitis enteropathica - before/after comparison

3. Zinc in Alopecia Areata

Studies have found lower serum zinc levels in patients with alopecia areata compared to controls. Zinc's immunomodulatory role (T-cell regulation) provides the mechanistic rationale - since AA is an autoimmune T-cell mediated disease. However, routine zinc supplementation for AA is not a standard first-line recommendation; it may be considered as adjunctive therapy when deficiency is confirmed.

4. Zinc and Androgenetic Alopecia (AGA)

A 2024 systematic review (Wang et al., Mol Nutr Food Res 2024) - covering 49 studies from 1993-2023 - found:
"Deficiencies or imbalances in specific vitamins and minerals, especially vitamin B, vitamin D, Fe, Se, and Zn are involved in the pathogenesis of AGA and may represent modifiable risk factors for treatment and prevention."
  • Zinc deficiency has been associated with increased risk of AGA
  • Zinc supplementation shows potential benefit in improving hair growth and preventing hair loss in AGA
  • However, the evidence is not entirely consistent - some studies report no significant associations
  • Zinc's mechanism in AGA includes 5-alpha-reductase inhibition (reducing DHT) and anti-inflammatory effects
Topical zinc: Zinc pyrithione shampoo is used in seborrheic dermatitis and dandruff - conditions that can worsen hair shedding - and may reduce associated hair loss as a secondary benefit.

5. Diagnosis of Zinc Deficiency in Hair Loss

TestNotes
Serum zincLow (<40 μg/mL confirms deficiency)
Serum alkaline phosphataseLow level (zinc-dependent enzyme) - useful adjunctive marker; results may be available faster
Therapeutic trialIf serum zinc is borderline but clinical picture is suggestive, a zinc supplementation trial is reasonable

6. Treatment: Zinc Supplementation Dosing

IndicationDose
Acquired zinc deficiency (adults)Zinc sulfate 50 mg elemental zinc daily (220 mg zinc sulfate tablet) = 1-2 mg/kg/day
Acrodermatitis enteropathica (genetic)3 mg/kg/day - lifelong
Transient neonatal/acquired (correctable cause)Supplement until replete; address underlying cause
Caution: Excessive zinc supplementation causes copper deficiency (zinc upregulates metallothionein, which sequesters copper). Overzealous supplementation should be avoided. Fatal copper deficiency from zinc-based denture adhesive overuse has been reported.
  • Andrews' Diseases of the Skin, p. 2931-2933

7. Summary

Type of Hair LossZinc's Role
Zinc deficiency-associated alopeciaDirect cause; reverses completely with supplementation
Acrodermatitis enteropathicaClassic triad includes alopecia; lifelong Zn replacement required
Alopecia areataLow zinc levels found; immunomodulatory role; adjunctive supplementation considered
Androgenetic alopeciaDeficiency is a modifiable risk factor; 5-alpha-reductase inhibition is mechanism; evidence moderately supportive
Telogen effluviumZinc deficiency is one of many nutritional triggers

Sources:

Lupus erythemayous of hair

Finding Sources
Finding Sources
Searching PubMed

"lupus erythematosus" AND "alopecia"

Reading File
Reading File
Reading File
Reading File
Finding Sources
Searching Images

discoid lupus erythematosus scalp scarring alopecia

This is a clinical scalp photograph documenting discoid lupus erythematosus (DLE)–associated scarring alopecia. The image shows a localized left-parietal scalp patch with hair loss persisting in the focal area, featuring an atrophic center and a clearly defined, active-appearing border. Surrounding skin may display mild erythema and scaling; follicular openings are diminished or absent within the scar, consistent with cicatricial alopecia. Visual cues—well-demarcated plaque with scarring—help distinguish DLE from non-scarring alopecias such as androgenetic alopecia or alopecia areata in this clinical setting. This photograph supports dermatologic assessment, documentation of disease extent, and monitoring of progression or response to therapy. Clinically, DLE on the scalp necessitates biopsy confirmation when uncertain, photoprotection, and consideration of antimalarials or immunosuppressants depending on activity and systemic involvement risk. The image is suitable for education, differential diagnosis exercises, and research into scarring mechanisms, disease activity, and treatment outcomes. When correlated with histopathology and serologic data, it aids in comprehensive lupus evaluation and longitudinal patient management.

This is a clinical scalp photograph documenting discoid lupus erythematosus (DLE)–associated scarring alopecia. The image shows a localized left-parietal scalp patch with hair loss persisting in the focal area, featuring an atrophic center and a clearly defined, active-appearing border. Surrounding skin may display mild erythema and scaling; follicular openings are diminished or absent within the scar, consistent with cicatricial alopecia. Visual cues—well-demarcated plaque with scarring—help distinguish DLE from non-scarring alopecias such as androgenetic alopecia or alopecia areata in this clinical setting. This photograph supports dermatologic assessment, documentation of disease extent, and monitoring of progression or response to therapy. Clinically, DLE on the scalp necessitates biopsy confirmation when uncertain, photoprotection, and consideration of antimalarials or immunosuppressants depending on activity and systemic involvement risk. The image is suitable for education, differential diagnosis exercises, and research into scarring mechanisms, disease activity, and treatment outcomes. When correlated with histopathology and serologic data, it aids in comprehensive lupus evaluation and longitudinal patient management.

This clinical photograph displays a superior view of the scalp demonstrating classic features of Discoid Lupus Erythematosus (DLE). The image reveals extensive, patchy scarring alopecia (cicatricial alopecia) characterized by a significant reduction in hair density and visible destruction of hair follicles. The skin lesions exhibit a tri-colored, variegated appearance: erythematous (pink-red) areas indicating active inflammation, hyperpigmented (brown-tan) macules and patches, and focal regions of porcelain-white hypopigmentation suggestive of established dermal fibrosis and scarring. The distribution is irregular across the vertex and crown, showing the progressive nature of the follicular damage. This visual serves as a primary educational example of the cutaneous manifestations of chronic cutaneous lupus erythematosus on the scalp, emphasizing the transition from active inflammatory plaques to permanent, irreversible hair loss.

This clinical photograph displays a superior view of the scalp demonstrating classic features of Discoid Lupus Erythematosus (DLE). The image reveals extensive, patchy scarring alopecia (cicatricial alopecia) characterized by a significant reduction in hair density and visible destruction of hair follicles. The skin lesions exhibit a tri-colored, variegated appearance: erythematous (pink-red) areas indicating active inflammation, hyperpigmented (brown-tan) macules and patches, and focal regions of porcelain-white hypopigmentation suggestive of established dermal fibrosis and scarring. The distribution is irregular across the vertex and crown, showing the progressive nature of the follicular damage. This visual serves as a primary educational example of the cutaneous manifestations of chronic cutaneous lupus erythematosus on the scalp, emphasizing the transition from active inflammatory plaques to permanent, irreversible hair loss.

Clinical photography of the scalp depicts discoid lupus erythematosus-associated cicatricial (scarring) alopecia. The frontal to vertex scalp shows patchy erythematous and atrophic plaques with loss of normal follicular openings and hair shafts. Dermal sclerosis and peripilar telangiectasias are evident within affected areas, producing a smooth, scarred surface with diminished skin appendages. The remaining hair is sparse at the lesion margins, emphasizing the irregular scarring process. The vascular pattern includes visible dilated vessels, consistent with telangiectasia, and surrounding mild erythema. Overall morphology is characteristic of chronic inflammatory scarring alopecia with angular plaque margins and hypo- or hyperpigmented zones. The locoregional involvement on the scalp supports a diagnosis of discoid lupus erythematosus, a cutaneous manifestation of lupus erythematosus. The image captures essential features used for differential diagnosis from non-scarring alopecias and other cicatricial conditions, including lichen planopilaris and frontal fibrosing alopecia. The finding has clinical significance for patient management, as DLE may respond to antimalarial therapy and sun protection, and chronic inflammation risks progression to deeper dermal damage. This image is valuable for dermatology education, cicatricial alopecia research, and documented cutaneous lupus case repositories; it informs pattern recognition, staging, and treatment planning. Educational use includes pattern recognition, differential diagnosis, and treatment planning principles.

Clinical photography of the scalp depicts discoid lupus erythematosus-associated cicatricial (scarring) alopecia. The frontal to vertex scalp shows patchy erythematous and atrophic plaques with loss of normal follicular openings and hair shafts. Dermal sclerosis and peripilar telangiectasias are evident within affected areas, producing a smooth, scarred surface with diminished skin appendages. The remaining hair is sparse at the lesion margins, emphasizing the irregular scarring process. The vascular pattern includes visible dilated vessels, consistent with telangiectasia, and surrounding mild erythema. Overall morphology is characteristic of chronic inflammatory scarring alopecia with angular plaque margins and hypo- or hyperpigmented zones. The locoregional involvement on the scalp supports a diagnosis of discoid lupus erythematosus, a cutaneous manifestation of lupus erythematosus. The image captures essential features used for differential diagnosis from non-scarring alopecias and other cicatricial conditions, including lichen planopilaris and frontal fibrosing alopecia. The finding has clinical significance for patient management, as DLE may respond to antimalarial therapy and sun protection, and chronic inflammation risks progression to deeper dermal damage. This image is valuable for dermatology education, cicatricial alopecia research, and documented cutaneous lupus case repositories; it informs pattern recognition, staging, and treatment planning. Educational use includes pattern recognition, differential diagnosis, and treatment planning principles.

Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Loading Image
Excellent - I now have rich, comprehensive information from multiple authoritative textbooks plus clinical images. I have enough to compile a thorough answer.

Lupus Erythematosus and Hair Loss

Lupus erythematosus (LE) affects the hair through two fundamentally different mechanisms - one reversible (non-scarring) and one permanent (scarring/cicatricial). Understanding this distinction is clinically critical because it determines urgency of treatment.

1. Classification of LE-Related Alopecia

TypeForm of LupusReversibilityMechanism
Non-scarring diffuse alopecia ("lupus hairs")SLE (systemic)Reversible with disease controlInflammatory telogen effluvium
Frontal "lupus hairs"SLE during flaresReversibleFragile short hairs, frontal area
Scarring (cicatricial) alopeciaDiscoid LE (DLE)PermanentFollicular destruction by chronic inflammation
  • Harrison's Principles of Internal Medicine 22e, p. 2078-2080

2. Non-Scarring Alopecia in Systemic Lupus Erythematosus (SLE)

Clinical Features

  • Occurs during flares of systemic disease
  • Can involve the entire scalp or preferentially the frontal scalp
  • Characteristic appearance: multiple short, fragile, broken hairs along the frontal hairline - the so-called "lupus hairs" - which represent initial regrowth after shedding
  • Pattern may resemble telogen effluvium - diffuse thinning without a defined patch
  • Hair regrowth occurs as the systemic disease is controlled

Mechanism

Systemic immune-mediated inflammation promotes follicles to exit anagen prematurely (anagen-to-telogen shift). The resulting hair shafts are fragile and break easily.

Key Point

This form is not associated with scarring; therefore follicle stem cells remain intact and full regrowth is expected once SLE is controlled.

3. Discoid Lupus Erythematosus (DLE) - Scarring Alopecia

DLE is the most important and destructive LE-related hair disorder. It is classified as a primary lymphocytic cicatricial alopecia.

Clinical Features on Scalp

The scalp plaque of DLE is highly characteristic:
  • Active (peripheral) zone: erythema, edema, scaling, follicular plugging (keratin plugs in follicular ostia), and perifollicular erythema
  • Established (central) zone: atrophy, loss of follicular ostia (the hallmark of scarring alopecia), telangiectasia
  • Dyspigmentation: Central hypopigmentation (white/ivory) surrounded by a rim of hyperpigmentation - a key diagnostic feature
  • Permanent hair loss in the central atrophic zone as follicles are destroyed
Below is a classic textbook image of DLE scarring alopecia showing the erythematous, crusted active plaque with central scarring and hair loss (from Andrews' Diseases of the Skin):
Scalp plaque with scarring alopecia, hyperpigmentation and depigmentation in discoid lupus erythematosus - Andrews' textbook clinical image
Discoid lupus erythematosus - scarring alopecia with tri-colored appearance: erythema, hyperpigmentation, and hypopigmented scarring zones
DLE scalp - active plaque with erythema, scaling, telangiectasia, and loss of follicular openings

Histopathology of DLE Scalp Biopsy

Biopsy should be taken from an established, active lesion (lesion of several months' duration), not the scarred center alone:
  • Hyperkeratosis with follicular plugging
  • Interface dermatitis (vacuolar degeneration at dermo-epidermal junction)
  • Basement membrane zone thickening (PAS-positive)
  • Dense perifollicular and periadnexal lymphocytic infiltrate
  • Dermal mucin deposition (a helpful diagnostic clue)
  • Late: loss of follicles replaced by fibrosis/scarring
Direct immunofluorescence (DIF): IgG, IgM, C3 deposited in a granular/band pattern at the DEJ ("lupus band test") - positive in lesional DLE skin.
Biopsy technique note: Vertical serial sections are superior for LE; the specimen should be oriented parallel to hair growth and taken to deep subcutaneous fat. A 4-mm punch biopsy is adequate.
  • Andrews' Diseases of the Skin, p. 3663-3667

Epidemiology

  • More common in African American women
  • 5-10% of adults with DLE develop systemic lupus erythematosus (SLE), especially those with widespread lesions - monitoring is essential

4. Trichoscopy (Dermoscopy of the Scalp) in DLE

Key trichoscopic features helpful for diagnosis and biopsy-site selection:
  • Large yellow dots (dilated follicular infundibula with keratinous material)
  • Red-white structureless areas (fibrosis)
  • Absence of follicular ostia (in scarred zones)
  • Arborizing telangiectasia
  • Perifollicular white halos

5. Differential Diagnosis

ConditionKey Distinguishing Feature
Lichen planopilarisViolet perifollicular macules; no dyspigmentation; oral LP common
Frontal fibrosing alopeciaBand-like recession at hairline; eyebrow loss; postmenopausal women
Alopecia areataNon-scarring; exclamation-point hairs; follicular ostia preserved
Tinea capitisFungal infection; can mimic inflammatory alopecia; culture + KOH positive
Folliculitis decalvansNeutrophilic cicatricial; follicular pustules; tufted hairs
Secondary syphilis"Moth-eaten" non-scarring alopecia; serology positive
  • Harrison's 22e, p. 2080; Andrews', p. 3657

6. Treatment

General Measures (All Forms of LE)

  • Strict photoprotection - LE is photosensitive; UV light triggers both skin flares and hair loss
  • Broad-spectrum high-SPF sunscreen daily
  • Smoking cessation (smoking reduces antimalarial efficacy)
  • Avoid trauma to scalp lesions; biopsies/scar revision can flare disease

Local (Topical/Intralesional) Treatment

TreatmentDetails
High-potency topical corticosteroidsFirst-line for localized DLE; apply under occlusion if needed; superpotent class I agents
Intralesional triamcinolone acetonideSingle most effective local treatment; 2.5-10 mg/mL injected every 4-6 weeks; max 40 mg per session
Topical calcineurin inhibitors (tacrolimus, pimecrolimus)Second-line topical; useful on face/sensitive areas
Topical retinoidsHelpful for hypertrophic lesions
Key: If treatment is started early while inflammation is still active at the periphery, hair regrowth may still occur because follicles at the margin are not yet permanently destroyed. Once fibrosis is complete, regrowth is not possible.

Systemic Treatment

DrugDose / Notes
Hydroxychloroquine (Plaquenil)5 mg/kg/day or less - First-line systemic; 2/3 of patients respond; if no response in 3 months, switch
Chloroquine250 mg/day; higher ocular toxicity; second choice antimalarial
Quinacrine100 mg/day; add to HCQ (no added retinal toxicity); causes yellowish pigmentation
Acitretin (retinoid)Similar efficacy to HCQ in RCTs; more side effects
MethotrexateOften next agent after antimalarials; for recalcitrant cases
DapsoneDrug of choice in bullous SLE; also useful in some DLE/SCLE
ThalidomideEffective but limited by teratogenicity and peripheral neuropathy
Oral prednisoneReserved for acute flares only; not for long-term scarring alopecia management
Belimumab, MMF, azathioprineFor refractory/systemic disease
Monitoring for hydroxychloroquine: Annual ophthalmologic exam (baseline before starting; may skip in first 1-5 years if low risk). Stop if any visual field defect or retinal pigmentary change.
  • Andrews' Diseases of the Skin, p. 3853-3862
  • Goldman-Cecil Medicine, p. 1469

7. Prognosis

  • Non-scarring SLE alopecia: Completely reversible when SLE is controlled
  • DLE scarring alopecia: Hair loss in fibrotic zones is permanent and irreversible - treatment only arrests progression
  • Early diagnosis and aggressive treatment of active DLE on the scalp are essential to preserve hair-bearing scalp
  • Fibrosis leaves a permanent "footprint" on elastic fiber staining (Verhoeff-van Gieson) even after inflammation resolves

Sources:
  • Harrison's Principles of Internal Medicine 22e, Chapter 61
  • Andrews' Diseases of the Skin - Clinical Dermatology, Chapters 2, 9, and SLE treatment section
  • Goldman-Cecil Medicine International Edition, Chapter 409
  • Dermatology 2-Volume Set 5e (Dermatology 5e), Chapter 69
This is a shared conversation. Sign in to Orris to start your own chat.